From trials to clinical practice: Temporal trends in the coverage of specialized allied health services for Parkinson's disease

被引:5
|
作者
Bloem, Bastiaan R. [1 ]
Eimers, Marietta [1 ]
van Galen, Mirte S. [2 ]
Munneke, Marten [1 ]
Darweesh, Sirwan K. L. [1 ,3 ]
机构
[1] Radboud Univ Nijmegen, Donders Inst Brain, Dept Neurol Cognit & Behav, Med Ctr, Nijmegen, Netherlands
[2] Vektis CV, Zeist, Netherlands
[3] Erasmus MC Univ Med Ctr, Dept Epidemiol, Rotterdam, Netherlands
关键词
disorders; movement disorders; neurological; Parkinson' s disease; scaling of healthcare innovations; specialized allied health services; OCCUPATIONAL-THERAPY; CARE;
D O I
10.1111/ene.14627
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose To determine how the coverage of specialized allied health services for patients with Parkinson's disease (PD) has developed in the Netherlands since the publication of trials that demonstrated cost-effectiveness. Methods We used healthcare expenditure-based data on all insured individuals in the Netherlands to determine the annual proportion of patients with PD who received either specialized or generic allied health services (physiotherapy, occupational therapy, speech-language therapy) in 2 calendar years separated by a 5-year interval (2012 and 2017). Specialized allied health services were delivered through the ParkinsonNet approach, which encompassed professional training and concentration of care among specifically trained professionals. Results Between 2012 and 2017, there was an increase in the number of patients with any physiotherapy (from 17,843 [62% of all patients with PD that year] to 22,282 [68%]), speech-language therapy (from 2171 [8%] to 3378 [10%]), and occupational therapy (from 2813 [10%] to 5939 [18%]). Among therapy-requiring patients, the percentage who were treated by a specialized therapist rose substantially for physiotherapy (from 36% in 2012 to 62% in 2017; chi(2) = 2460.2; p < 0.001), speech-language therapy (from 59% to 85%; chi(2) = 445.4; p < 0.001), and occupational therapy (from 61% to 77%; chi(2) = 231.6; p < 0.001). By contrast, the number of patients with generic therapists did not change meaningfully. By 2017, specialized care delivery had extended to regions that had been poorly covered in 2012, essentially achieving nationwide coverage. Conclusions Following the publication of positive trials, specialized allied healthcare delivery was successfully scaled for patients with PD in the Netherlands, potentially serving as a template for other healthcare innovations for patients with PD elsewhere.
引用
收藏
页码:775 / 782
页数:8
相关论文
共 50 条
  • [31] Allied Health Care in Parkinson's Disease: Referral, Consultation, and Professional Expertise
    Nijkrake, Maarten J.
    Keus, Samyra H. J.
    Oostendorp, Rob A. B.
    Overeem, Sebastiaan
    Mulleners, Wim
    Bloem, Bastiaan R.
    Munneke, Marten
    MOVEMENT DISORDERS, 2009, 24 (02) : 282 - 286
  • [32] Stemming the Tide: The Proactive Role of Allied Health Therapy in Parkinson's Disease
    Rafferty, Miriam R.
    Foster, Erin R.
    Roberts, Angela C.
    Smaller, Kevin A.
    Johnson, Lynn L.
    Lawson, Rachael A.
    JOURNAL OF PARKINSONS DISEASE, 2024, 14 : S7 - S19
  • [33] Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials
    Papapetropoulos, Spyridon
    CNS NEUROSCIENCE & THERAPEUTICS, 2012, 18 (05) : 380 - 387
  • [34] Clinical research coordinator workload in clinical trials in Parkinson's disease
    Dustin, KJ
    Shulman, LM
    MOVEMENT DISORDERS, 2006, 21 : S121 - S121
  • [35] Challenges in detecting disease modification in Parkinson's disease clinical trials
    Athauda, Dilan
    Foltynie, Thomas
    PARKINSONISM & RELATED DISORDERS, 2016, 32 : 1 - 11
  • [36] Genetic testing for Parkinson’s disease in clinical practice
    Thomas Gasser
    Journal of Neural Transmission, 2023, 130 : 777 - 782
  • [37] The Genetics of Parkinson's Disease and Implications for Clinical Practice
    Day, Jacob Oliver
    Mullin, Stephen
    GENES, 2021, 12 (07)
  • [38] Genetic testing for Parkinson's disease in clinical practice
    Gasser, Thomas
    JOURNAL OF NEURAL TRANSMISSION, 2023, 130 (06) : 777 - 782
  • [39] Metadata Framework to Support Deployment of Digital Health Technologies in Clinical Trials in Parkinson's Disease
    Hill, Derek L.
    Stephenson, Diane
    Brayanov, Jordan
    Claes, Kasper
    Badawy, Reham
    Sardar, Sakshi
    Fisher, Katherine
    Lee, Susan J.
    Bannon, Anthony
    Roussos, George
    Kangarloo, Tairmae
    Terebaite, Viktorija
    Muller, Martijn L. T. M.
    Bhatnagar, Roopal
    Adams, Jamie L.
    Dorsey, E. Ray
    Cosman, Josh
    SENSORS, 2022, 22 (06)
  • [40] The Treatment of Sleep Disorders in Parkinson's Disease: From Research to Clinical Practice
    Loddo, Giuseppe
    Calandra-Buonaura, Giovanna
    Sambati, Luisa
    Giannini, Giulia
    Cecere, Annagrazia
    Cortelli, Pietro
    Provini, Federica
    FRONTIERS IN NEUROLOGY, 2017, 8